Article | May 14, 2021

Working With Viral Vectors: New Trends To Optimize Your Workflow

Vaccine manufactiring vials iStock-1292355769

Viral vectors, which use modified viruses as vehicles to access genetic and cellular material, are one of the most commonly deployed tools in the search for a vaccine for SARS-CoV-2, the virus that causes COVID-19.

But COVID-19 didn't put viral vector research on the map. Scientists had been increasingly using viral vectors in therapeutic research well before the coronavirus pandemic, as their use in gene therapy and cell therapy has proven promising. Now, those same applications are being repurposed to develop a coronavirus vaccine.

However promising they might be, viral vector workflows come with inherent challenges in scale and process. Fortunately, technology is evolving rapidly, and new solutions to simplify viral vector bioprocessing are continuing to emerge.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene